Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Vinay Jahagirdar

Liver Transplant · Medical College of Virginia

View

Dr. Lauren Feld

Liver Transplant · UMass Memorial

View

Dr. Sonali Paul

Liver Transplant · UCMC

View

Dr. Pierre Gholam

Liver Transplant · CWRU

View

Dr. Elliot Tapper

Liver Transplant · UM

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Vitamin D supplementation is associated with reduced risk of hepatobiliary malignancy in patients with primary sclerosing cholangitis.

    Jul 15, 2026DOI: 10.1097/hc9.0000000000000929Journal ArticleHepatology Communications

    Written by: Katherine M CooperConnor MulliganHenry E PrattVanessa MitsialisDaniel S Pratt

    Find these authors on Roon

    KC
    Dr. Katherine Cooper
    Liver Transplant · MGH

    Summary

    BACKGROUND: Vitamin D deficiency has been implicated in cancer risk across several organ systems, but its role in hepatobiliary malignancy (HBM) remains unclear. We evaluated whether vitamin D supplementation (VDS) was associated with a lower risk of HBM specifically in patients with primary sclerosing cholangitis (PSC).METHODS: Patients enrolled in the PSC registry at our quaternary care and liver transplant (LT) center from 2010 to 2020 were analyzed. The primary exposure was VDS, modeled as a time-dependent variable. The primary outcome was HBM. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics, and Cox proportional hazards models were employed to estimate marginal hazard ratios (HRs). Cumulative incidence functionsfor HBM were estimated using a competing risks analysis treating death, and LT was as competing events.RESULTS: A total of 160 patients (mean age 42 years; 66% male) were included, of whom 76 (47.5%) reported baseline VDS. Over a median follow-up of 7 years, 15 patients developed HBM, corresponding to an incidence rate of 12.3 per 1000 person-years. VDS was associated with a significantly lower risk of HBM in both conventional (HR 0.16, 95% CI 0.05-0.57) and IPTW (HR 0.15, 95% CI 0.03-0.41) analyses. This association was consistent across baseline vitamin D strata, including <30 ng/mL (HR 0.12, 95% CI 0.02-0.79) and ≥30 ng/mL (HR 0.18, 95% CI 0.05-0.65). Accounting for competing risks, the 5-year cumulative incidence of HBM was 1.1% among patients receiving VDS versus 11.5% without VDS (p<0.01).DISCUSSION: VDS was associated with a significantly lower risk of HBM in this longitudinally followed cohort of patients with PSC. These findings support the consideration of VDS in all patients with PSC and underscore the need for mechanistic and interventional studies to further evaluate this association.
    KCDr. Katherine Cooper

    Dr. Katherine Cooper

    Gastroenterology · Hepatology & Liver Transplantation
    Massachusetts General Hospital
    katherinecooper